恶性淋巴瘤骨髓侵犯的观察

探讨非霍奇金淋巴瘤 (NHL )侵犯骨髓而发生骨髓浸润和淋巴瘤细胞白血病的骨髓特征及形态改变。方法 :骨髓 (BM)检查 :分类计数 2 5 0个有核细胞并记录形态学改变 ;外周血 (PB)测血红蛋白 (Hb)、白细胞 (WBC)计数及血小板 (PL T)计数 ,血片分类 (DC) 10 0个 WBC;骨髓侵犯标准 :NHL淋巴瘤细胞≥ 0 .0 5为骨髓浸润 ,淋巴瘤细胞 0 .2 0以上诊断为淋巴瘤白血病。结果 :17例 NHL并骨髓浸润 ,淋巴瘤细胞占 0 .0 5 %～ 0 .1% ,11例 NHL并白血病 ,淋巴瘤细胞占 0 .2 0 %～ 0 .91%。结论 :骨髓淋巴瘤细胞形态表现复杂多样 ,由于 NHL骨髓侵犯率高 ,而早期骨髓浸润由于病变程度较轻 ,经治疗患者病情多得到控制 ,使淋巴瘤白血病的发生率大大减低 ,从而提高了淋巴瘤患者的生存率。因此 ,骨髓检查有必要列为常规检查项目 ,且骨髓穿刺对 NHL的正确分期 ,确定治疗方案以及预后判断有一定价值。     

非霍奇金淋巴瘤20例的骨髓像观察

非霍奇金淋巴瘤(NHL),属恶性实体瘤。本病进展快,临床表现多样。NHL患者的骨髓浸润占有一定比例,合并淋巴肉瘤细胞白血病的患者更为常见。现将我院1996年1月～8月收治的20例NHL患者的骨髓特点进行观察和分析。 1 临床资料 NHL20例,男16例,女4例,年龄5.5～71岁,平均年龄37.5岁。20例患者均经病理证实为NHL,住院前后对全部患者行骨髓穿刺检查,发现正常骨髓像者12例,合并淋巴肉瘤白血病者(淋巴瘤细胞≥20％)5例,淋巴瘤细胞浸润骨髓者(淋巴瘤细胞≤5％)占3例。 2 结果与讨论 20例NHL患者的骨髓不同程度受到浸润。其中严重的是淋巴肉瘤白血病占20例中的5例,骨髓涂片检查中发现有淋巴瘤细胞浸润者占3例。 5例淋巴肉瘤白血病患者的瘤细胞形态均为小     

非何杰金氏淋巴瘤骨髓DNA含量的初步观察

本文应用流式细胞仪测定非何杰金氏淋巴瘤(NHL)骨髓细胞DNA 含量,试图在DNA 水平研究NHL 病理亚型、骨髓侵犯及近期疗效的差异,协助临床诊断和治疗。材料与方法1989年11月～1990年12月收治NHL22例,男17例,女5例,年龄11～71岁,平均44.8岁。除1例Ⅰ_A 期外,余均为Ⅲ或Ⅳ期。卡氏评分多在70～90分。病理分类依据全国NHL 工作分类,22例NHL 中,高恶度11例,其中淋巴母细胞性3例,免疫母细胞性2例,小无裂细胞性2例,组织细胞性2例,多形细胞性2例;     

桥本甲状腺肿合并非霍奇金淋巴瘤4例临床病理分析

目的探讨桥本甲状腺肿合并非霍奇金淋巴瘤(NHL)的临床病理特点。方法通过HE及免疫组化染色观察4例桥本甲状腺肿合并NHL的形态特征,并复习文献。结果4例桥本甲状腺肿,3例合并黏膜相关淋巴样组织结外边缘区B细胞淋巴瘤(MALToma);1例合并弥漫性大B细胞淋巴瘤(DLBCL),结合细针穿刺细胞学检查(FNAC)、术中冰冻病理检查可形成桥本淋巴瘤的提示性诊断,最后经石蜡切片及免疫组化确诊并明确组织学类型。结论提高对桥本甲状腺肿合并NHL临床病理特点的认识,可避免桥本甲状腺肿合并NHL的漏诊和误诊。     

非霍奇金淋巴瘤1126例骨髓涂片检查结果分析

目的 探讨非霍奇金淋巴瘤（NHL）骨髓浸润的临床特点.方法 回顾性分析经病理确诊为NHL的1 126例患者的骨髓涂片资料,分析其骨髓浸润情况.结果 1 126例NHL患者中,骨髓浸润及并发淋巴瘤细胞白血病者占9.1%,其中以B细胞淋巴瘤占8.0%（64/796）,NK/T细胞淋巴瘤占11.5%（38/330）;骨髓淋巴瘤细胞数5.0%~〈20.0%占68.6%（70/102）,≥20%的患者占31.4%（32/102）;骨髓浸润患者中临床分期Ⅲ期28例,Ⅳ期74例,无Ⅰ期和Ⅱ期患者,中、重度患者多数出现贫血、中性粒细胞异常、血小板减少及白细胞分布异常.患者瘤细胞分型：小淋巴细胞型31例,幼稚型66例、组织细胞型5例;有核细胞增生减低8例,增生活跃45例,明显活跃36例,增生极度活跃13例;粒、红或巨系异常者27例.结论 恶性淋巴瘤骨髓浸润比例高,不同的病理学类型骨髓受累的风险不一,总体而言T细胞淋巴瘤的骨髓浸润率更高,骨髓细胞学检查对恶性淋巴瘤的正确分期、治疗方案的选择和预后判断有重要的意义.     

胸部淋巴瘤的CT表现

作者收集近三年来经病理证实的胸部淋巴瘤50例，均经CT检查，其中HD11例，NHL39例，兹对胸部淋巴瘤的CT征像从四个方面探讨如下。临床资料一、纵隔及肺门淋巴结肿大淋巴瘤胸部侵犯主要表现为纵隔、肺门淋巴结肿大。本组11例HD、39例NHL肿大淋巴结分布见附表。本组肿大淋巴结直径＜3cm者35例（71％），NHL境界相对比HD清楚；直径＞3cm者］5例形成团块。其中11例肿块与胞壁、胸膜、心包境界不清，侵犯邻近组织，显示‘”E”病变。二、肺部浸润淋巴瘤侵犯肺部，可表现为给节型、粟粒型、斑片及京条状多种形态。一般密度较淡，多数仅在…     

新疆314例恶性淋巴瘤的临床及病理资料分析

目的研究恶性淋巴瘤的临床、病理特点。方法根据WHO（2008）分类标准对314例恶性淋巴瘤患者进行临床及病理资料分析。结果非霍奇金淋巴瘤（NHL）271例。43例HL中以混合细胞性经典霍奇金淋巴瘤为主。NHL中,B细胞淋巴瘤多于T细胞淋巴瘤。结外淋巴瘤少于结外淋巴瘤.NHL中发病率较高的淋巴瘤类型依次为：弥漫大B细胞淋巴瘤,慢性淋巴细胞性白血病/小淋巴细胞性淋巴瘤。不能分类的B细胞淋巴瘤,黏膜相关淋巴组织细胞淋巴瘤,NK/T细胞淋巴瘤,外周T细胞淋巴瘤。少数民族和汉族均以弥漫大B细胞淋巴瘤为主。结论应用WHO（2008）分类对恶性淋巴瘤进行分析研究,具有重要的临床意义。     

弥漫大B细胞淋巴瘤骨髓侵犯形态学及免疫表型特点分析

目的 探讨弥漫大B细胞淋巴瘤（DLBCL）骨髓侵犯形态学及免疫表型特点,为临床DLBCL侵犯骨髓的准确诊断提供一定的科学依据。方法 收集2014年6月—2019年6月我院收治的59例DLBCL患者的骨髓组织和外周血,分析DLBCL患者的骨髓细胞形态学、骨髓病理学、流式细胞学、荧光原位免疫杂交及其他相关检测的结果与临床特征。结果 59例发生骨髓侵犯的DLBCL患者多数表现为白细胞增高、贫血、血小板减少,有43例（72.88%）外周血中可见数量不等的瘤细胞。59例患者骨髓涂片中瘤细胞占有核细胞比例≥10％的有31例（52.54%）。瘤细胞侵犯骨髓方式以弥漫性增生为主,造血组织明显减少或缺乏。免疫组化染色及流式细胞学检查示,淋巴瘤细胞 CD20、CD19、CD79b及 cCD79a均呈阳性表达,部分患者表达 HLA-DR、CD22、sIgM、CD43、CD10、FMC7及 CD123,均不表达CD38、TdT、CD103、CD25、CD3、CD2、MPO、CD33、CD13、CD7及CD56。12例患者进行FISH检测均未见C-myc基因重排。结论 骨髓形态学、病理学并结合免疫表型检测是DLBCL患者准确诊断的重要依据。     

非霍奇金淋巴瘤患者血清p53的表达及临床意义

目的 探讨在非霍奇金淋巴瘤(NHL)患者血清p53的表达及临床意义.方法 NHL患者30例,ELISA法检测血清p53含最,并与20例健康人血清作对照.结果 NHL患者血清p53平均浓度较健康对照组明显增高(P<0.01),其中合并白血病或骨髓浸润者明显高于未浸润者;临床治疗有效者p53平均浓度明显下降;p53表达水平与患者年龄、性别无相关性,而与患者临床分期、肿瘤侵犯程度、血清乳酸脱氢酶(LDH)浓度呈正相关.结论 NHL患者血清p53表达水平增高,对疾病的临床分期、肿瘤侵犯程度判断有一定价值,有望成为判断NHL预后的新指标.     

非霍奇金淋巴瘤骨髓侵犯外周血液细胞分析

目的:了解非霍奇金淋巴瘤骨髓侵犯后与外周血液细胞之间的关系。方法:对95例NHL骨髓侵犯患者的骨髓涂片分类计数,记录其形态学改变,并对外周血液涂片进行分类。结果:549例NHL患者发生BMI或LMCL共95例,占17.3%,WBC<4.0×109/L11例,4.0×109/L≤WBC<10.0×109/L35例,WBC≥10.0×109/L49例。外周血分类正常:BMI占22.1%,LMCL占8.4%;外周血分类异常:BMI占6.3%,LMCL占63.2%。结论:BMI和LMCL在外周血中不一定呈白血病改变,对NHL患者不但要经常检测血象,更要定期监测患者的骨髓象,而且对LMCL的骨髓片应作化学染色,保证诊断的准确性。     

核仁组成区嗜银蛋白染色在非霍奇金淋巴瘤骨髓涂片中的价值探讨

目的：探讨核仁组成区嗜银蛋白染色在非霍奇金淋巴瘤骨髓涂片中的价值。方法用经钟氏等报道[1]的双层滤纸垫染法对117例NHL骨髓涂片进行染色后检测,并另做17例大致正常骨髓片做对照。结果 NHL组、NHL晚期组二者的银染颗粒含量和银染颗粒阳性率均较正常对照组有显著性差异（两组P〈0.05）;NHL晚期组的银染颗粒含量和银染颗粒阳性率均较NHL早期组有显著性差异（两者P〈0.05）;而NHL早期组的银染颗粒含量和银染颗粒阳性率均与正常对照组无显著性差异（P均〉0.05）。结论 AgNOR染色在NHL骨髓涂片的诊断中具有较大的应用价值。     

Oral idarubicin in non-Hodgkin's lymphomas

Idarubicin (DMDR), a new analogue of daunorubicin, was administered orally once every 3 weeks at the dose of 40 to 45 mg/m² to 20 evaluable patients with non-Hodgkin's lymphomas (NHL).Eighty-six percent of patients with favorable histology and 54% with unfavorable histology (intermediate and high grade as IWF) achieved a response with an overall response rate of 65% (two complete and 11 partial responses). Response rates were higher (85%) in previously untreated patients than in those with prior exposure to chemotherapy (29%). Gastrointestinal and hematologic toxicity was generally mild to moderate. No signs or symptoms of cardiotoxicity were recorded.Although the quality of response, as well as the relatively low response rate in previously treated patients and in those with unfavorable histology, makes it unlikely that DMDR can replace standard anthracyclines in NHL, the drug appears attractive in selected instances, such as in elderly patients and in those with slow-growing NHL with favorable histology.     

卡氮芥、阿糖胞苷为主联合化疗治疗Ⅳ期非霍奇金淋巴瘤

探讨Ⅳ期非霍奇金淋巴瘤经济有效的化疗方案。方法：对心肝肾功能正常、骨髓检查增生活跃的复治的Ⅳ期非霍奇金淋巴瘤患者,应用卡氮芥（62.5-125mg/d,第1d）、阿糖胞苷（100mg/d,第1-5d）、吡柔比星（40mg/d,第1d）、长春新碱（1.5mg/d,第1、8d）和地塞米松（10mg/d,第1-14d）组成的联合化疗方案进行化疗。结果：22例患者中,完全缓解5例,部分缓解 10例,有效率 68.2%。结论：以卡氮芥和阿糖胞苷为主的联合化疗方案是Ⅳ期非霍奇金淋巴瘤经济有效的化疗方案之一。     

缺铁性贫血骨髓幼红细胞百分比

目的分析缺铁性贫血（IDA）患者的骨髓幼红细胞百分比。方法选择110例未治疗的初诊IDA患者。骨髓涂片经瑞氏染色后，显微镜下计数每例患者200个骨髓有核细胞。结果89例（80．91％）IDA患者骨髓幼红细胞≥30％；19例（17．27％）IDA患者骨髓幼红细胞≥50％；全部患者骨髓幼红细胞平均百分比为39．38％，约为参考值的2倍；最小百分比为17．0％，最大百分比为71．5％。结论IDA患者骨髓幼红细胞百分比范围广泛；需与其他贫血相鉴别。     

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia

Rituximab is an anti-CD20 monoclonal antibody that has demonstrated efficacy in patients with various lymphoid malignancies, including indolent and aggressive forms of B-cell non-Hodgkin's lymphoma (NHL) and B-cell chronic lymphocytic leukaemia (CLL). While the optimal use of the drug in many clinical settings has yet to be clarified, two pivotal trials have established rituximab as a viable treatment option in patients with relapsed or refractory indolent NHL, and as a standard first-line treatment option when combined with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (the most common type of aggressive NHL). The former was a noncomparative trial in relapsed indolent NHL (follicular and small lymphocytic subtypes) with clinical responses achieved in about half of patients treated with rituximab 375 mg/m(2) intravenously once weekly for 4 weeks, which was similar to some of the most encouraging results reported with traditional chemotherapeutic agents. The latter was a randomised comparison of eight cycles of CHOP plus rituximab 375 mg/m(2) intravenously (one dose per cycle) versus CHOP alone in previously untreated elderly patients (60 to 80 years of age) with diffuse large B-cell lymphoma. In this pivotal trial, 2-year event-free and overall survival were significantly higher with rituximab plus CHOP, and there was no increase in clinically significant adverse effects compared with CHOP alone. Treatment with rituximab is generally well tolerated, particularly in terms of adverse haematological effects and serious or opportunistic infections relative to standard chemotherapy. Infusion-related reactions occur in the majority of patients treated with rituximab; these are usually mild to moderate flu-like symptoms that decrease in frequency with subsequent infusions. In approximately 10% of patients, however, severe infusion-related reactions develop (e.g. bronchospasm, hypotension). These reactions are usually reversible with appropriate interventions and supportive care but there have been rare reports of fatalities. CONCLUSIONS: Clinical trials with rituximab indicate that the drug has broad application to B-cell malignancies, although further clarification is needed to determine its optimal use in many of these clinical settings. Importantly, rituximab in combination with CHOP chemotherapy has emerged as a new treatment standard for previously untreated diffuse large B-cell lymphoma, at least in elderly patients. Compared with conventional chemotherapy, rituximab is associated with markedly reduced haematological events such as severe neutropenia, as well as associated infections. Rituximab may be particularly suitable for elderly patients or those with poor performance status, and its tolerability profile facilitates its use in combination with cytotoxic drugs. PHARMACODYNAMIC PROPERTIES: Rituximab is a mouse/human chimaeric IgG(1)-kappa monoclonal antibody that targets the CD20 antigen found on the surface of malignant and normal B lymphocytes. Although treatment with rituximab induces lymphopenia in most patients, typically lasting about 6 months, a full recovery of B lymphocytes in the peripheral blood is usually seen 9-12 months after therapy, as CD20 is not expressed on haematopoietic stem cells. CD20 is, however, expressed on >90% of B-cell non-Hodgkin's lymphomas (NHL) and to a lesser degree on B-cell chronic lymphocytic leukaemia (CLL) cells.Although not fully elucidated, the cytotoxic effects of rituximab on CD20-positive malignant B cells appears to involve complement-dependent cytotoxicity, complement-dependent cellular cytotoxicity, antibody-dependent cellular cytotoxicity and induction of apoptosis. In addition, in vitro data indicate that rituximab sensitises tumour cells to the effects of conventional chemotherapeutic drugs. PHARMACOKINETIC PROPERTIES: Serum rituximab concentrations increased in proportion to dose across a wide range of single- and multiple-dose intravenous regimens in patients with B-cell NHL. When administll NHL. When administered at a dose of 375 mg/m(2) once weekly for 4 weeks in a pivotal trial in patients with relapsed or refractory indolent B-cell NHL (follicular or small lymphocytic subtypes), peak serum concentrations essentially doubled from the first (239.1 mg/L) to the fourth (460.7 mg/L) infusion, while elimination half-life (t(1/2)) increased from 76.3 to 205.8 hours (3.2 to 8.6 days). The concomitant increase in serum rituximab concentrations and t(1/2) with each successive infusion may be due, at least in part, to the elimination of circulating CD20-positive B cells and reduction or saturation of CD20-binding sites after the initial infusions of rituximab. The pharmacokinetic properties of rituximab are also characterised by wide inter-individual variability, and serum drug concentrations that are correlated with clinical response. Although pharmacokinetic data are limited in patients with aggressive forms of NHL, such as diffuse large B-cell lymphoma, rituximab appears to have a similar pharmacokinetic profile in these patients to that in patients with indolent B-cell NHL. The pharmacokinetics of rituximab are also reported to be similar whether the drug is administered with or without cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy. THERAPEUTIC USE: A number of studies have demonstrated efficacy of intravenous rituximab in patients with various lymphoid malignancies of B-cell origin, including indolent (e.g. follicular lymphoma) and aggressive (e.g. diffuse large B-cell lymphoma) forms of NHL, and CLL, but the drug has not yet been approved for use in CLL, and approved indications in NHL vary between countries. In the US, for example, rituximab is available for the treatment of patients with low-grade or follicular, relapsed or refractory, CD20-positive B-cell NHL. In Europe, the drug has similar approval for relapsed or refractory follicular NHL as in the US, but has also been approved for use in combination with CHOP chemotherapy for the most common aggressive form of NHL (CD20-positive, diffuse large B-cell lymphoma). Rituximab was approved for these indications primarily on the basis of results from two pivotal trials. In Japan, rituximab has been approved for indolent B-cell NHL and mantle cell lymphoma (an aggressive form of B-cell NHL), primarily on the basis of results of a Japanese phase II trial. Indolent NHL: Results of several studies evaluating rituximab 375 mg/m(2) once weekly for 4 weeks in patients with indolent forms of B-cell NHL (primarily follicular and small lymphocytic lymphomas) showed objective response (OR) rates ranging from approximately 40-60% in those receiving the drug for relapsed or refractory indolent B-cell NHL, and slightly higher (50-70%) for those receiving rituximab as first-line therapy. In a pivotal trial in 166 patients with relapsed or refractory low-grade or follicular B-cell NHL, intent-to-treat (ITT) analysis showed an OR rate of 48%, and a projected median time to progression of 13 months.Encouraging data are also emerging on the use of rituximab in combination with chemotherapeutic agents (e.g. CHOP, fludarabine-containing regimens) or other drugs (e.g. interferon-alpha2a) in previously untreated patients with indolent forms of B-cell NHL (primarily follicular and small lymphocytic subtypes). Rates for OR were consistently around 95%, with the majority being complete responses (CRs). Follow-up data from a study in 40 patients with low-grade or follicular B-cell NHL treated with rituximab plus CHOP as first-line therapy showed that responses were durable with a progression-free survival and median duration of response >5 years.Bcl-2 gene rearrangement (t14;18) occurs in malignant cells in up to 85% of patients with follicular lymphoma, and minimal residual disease in peripheral blood and bone marrow can be monitored using polymerase chain reaction (PCR). In several studies assessing blood and/or bone marrow, rituximab has achieved molecular response (conversion from PCR-positive to PCR-negative bcl-2 status) in at least half of the patients. Aggressive NHL: Studies with rituximab as monotherapy in aggressive B-cell NHL, a potentially curable disorder, have generally been restricted to patients with relapsed or recurrent disease, since CHOP has traditionally been the standard first-line treatment regimen. However, promising results from phase II monotherapy studies prompted further clinical investigation of rituximab in conjunction with chemotherapy. Thus, most studies with rituximab in patients with aggressive forms of B-cell NHL have involved combination therapy, including a pivotal randomised trial comparing eight cycles of standard CHOP therapy plus rituximab 375 mg/m(2) (one dose per cycle) versus CHOP alone in 399 previously untreated elderly patients (60-80 years of age) with diffuse large B-cell lymphoma. Results of the pivotal trial showed a clear advantage for rituximab plus CHOP versus CHOP in terms of event-free survival (primary endpoint) at 2 years (57% vs 38%, p < 0.001). Overall survival at 2 years (70% vs 57%, p < 0.01) and CR rate (76% vs 63%, p < 0.01) were also higher with the rituximab-CHOP combination. Other, smaller trials with rituximab in combination with CHOP or other chemotherapeutic regimens, either as first-line therapy or for patients with relapsed or refractory aggressive B-cell NHL, have also shown promising results in terms of clinical response rates.CLL: In relatively small trials (n < 40) conducted primarily in patients with relapsed or refractory B-cell CLL, rituximab monotherapy (various regimens) achieved OR rates of 23-45%, with median duration of response ranging from approximately 3-10 months. (ABSTRACT TRUNCATED)     

利妥昔单抗联合ESHAP方案治疗复发非霍奇金淋巴瘤临床观察

目的 观察利妥昔单抗(Rituximab)联合ESHAP方案(依托泊苷、甲基强的松龙、顺铂、阿糖胞苷)治疗复发的CD20阳性B细胞性非霍奇金淋巴瘤(non-Hodgkinslymphoma,NHL)的临床疗效及安全性.方法 回顾性分析我院以利妥昔单抗联合ESHAP方案及单用ESHAP方案治疗复发的CD20阳性B细胞性非霍奇金淋巴瘤的临床资料.32例复发的CD20阳性的B细胞非霍奇金淋巴瘤患者,随机分为利妥昔单抗联合ESHAP方案组(治疗组)及单用ESHAP方案组(对照组),每21 d为1个周期,重复治疗.全部32例患者完成4个周期化疗后进行疗效评价.结果 治疗组完全缓解率(CR)为37.5%,总有效率为87.5%;对照组分别为25%、56.3%,两组有效率有显著性差异(P<0.05).两组患者不良反应主要为轻中度骨髓抑制、脱发和消化道反应.不良反应发生率相近(P>0.05),均可耐受.治疗组1例(6.25%)出现利妥昔单抗输注相关的不良反应,经对症处理后好转.结论 利妥昔单抗联合ESHAP方案治疗复发的CD20阳性B细胞性非霍奇金淋巴瘤安全有效,患者耐受良好,应推荐使用.     

R-CHOP治疗初治B细胞性非霍奇金淋巴瘤的临床分析

目的观察美罗华联合CHOP治疗CD20阳性B细胞性非霍奇金淋巴瘤的临床疗效及不良反应。方法回顾性分析2005年1月～2007年1月采用R-CHOP方案治疗46例初治B细胞NHL的疗效、安全性及不良反应。结果完全缓解率为69.5%(32/46),部分缓解率为21.7%(10/46),稳定1例,疾病进展3例。结论 R-CHOP方案治疗CD20阳性初治B细胞性非霍奇金淋巴瘤疗效显著,不良反应小,耐受好。     

艾滋病相关非霍奇金淋巴瘤的治疗研究进展

非霍奇金淋巴瘤（NHL）是艾滋病相关恶性肿瘤疾病中最为常见的一种。联合抗逆转录病毒疗法（cART）可使HIV感染者获得免疫重建,提升对化疗的耐受能力,且多数患者可从中获益。艾滋病相关NHL具有高度异质性,临床表现多样,发病机制较为复杂,治疗困难。近年来,大量临床试验及前瞻性研究数据得以更新,分子学及肿瘤基因组学、免疫学等各类新技术研究不断深入,为艾滋病相关NHL的治疗提供了新思路。本文主要对其几个亚型在治疗策略及新药物研究中的进展作一综述。     

美罗华联合CHOP治疗B细胞性非霍奇金淋巴瘤

目的评价美罗华(Rituximah)联合CHOP(R-CHOP)方案治疗CD20阳性B细胞性非霍奇金淋巴瘤(NHL)的临床疗效及不良反应。方法将60例初治B细胞淋巴瘤患者分为R-CHOP组和CHOP组各30例。R-CHOP组采用R-CHOP方案化疗;CHOP组采用CHOP方案化疗。6个疗程后比较两组的临床疗效及不良反应。结果 R-CHOP组完全缓解率达80%,总有效率90%;CHOP组完全缓解率为60%,总有效率为73.3%,两组疗效差异有统计学意义(P<0.01)。两组不良反应差异无统计学意义(P>0.05)。结论美罗华联合CHOP方案治疗CD20阳性B细胞性非霍奇金淋巴瘤疗效显著,不良反应与单纯化疗相似,可作为该病目前的首选方案。